Upstream Bio (NASDAQ:UPB – Get Free Report) and Keros Therapeutics (NASDAQ:KROS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Upstream Bio and Keros Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
| Keros Therapeutics | 1 | 4 | 4 | 0 | 2.33 |
Upstream Bio currently has a consensus price target of $29.67, indicating a potential upside of 543.53%. Keros Therapeutics has a consensus price target of $20.50, indicating a potential upside of 82.87%. Given Upstream Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Upstream Bio is more favorable than Keros Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Upstream Bio | -4,955.67% | -48.40% | -46.57% |
| Keros Therapeutics | -256.60% | -21.40% | -19.79% |
Risk and Volatility
Upstream Bio has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Earnings and Valuation
This table compares Upstream Bio and Keros Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Upstream Bio | $2.85 million | 88.59 | -$143.44 million | ($2.90) | -1.59 |
| Keros Therapeutics | $244.06 million | 0.91 | $87.01 million | ($3.70) | -3.03 |
Keros Therapeutics has higher revenue and earnings than Upstream Bio. Keros Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
71.6% of Keros Therapeutics shares are held by institutional investors. 16.5% of Upstream Bio shares are held by insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Upstream Bio beats Keros Therapeutics on 7 of the 13 factors compared between the two stocks.
About Upstream Bio
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
About Keros Therapeutics
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
